CMF (chemotherapy)

Chemotherapy regimen for breast cancer

CMF Chemotherapy

CMF is a chemotherapy regimen used primarily in the treatment of breast cancer. The acronym CMF stands for the combination of three drugs: Cyclophosphamide, Methotrexate, and Fluorouracil. This regimen is one of the oldest and most established chemotherapy treatments for breast cancer.

Components of CMF

Cyclophosphamide

Cyclophosphamide is an alkylating agent that works by interfering with the replication of DNA in cancer cells, thereby preventing their growth and division. It is used in various chemotherapy regimens due to its effectiveness in targeting rapidly dividing cells.

Methotrexate

Methotrexate is an antimetabolite and antifolate drug. It inhibits the enzyme dihydrofolate reductase, which is necessary for the synthesis of nucleotides required for DNA replication. By blocking this enzyme, methotrexate disrupts the growth of cancer cells.

Fluorouracil

Fluorouracil (5-FU) is a pyrimidine analog that interferes with the synthesis of thymidylate, an essential component of DNA. It is incorporated into the RNA of cancer cells, disrupting their function and leading to cell death.

Administration

The CMF regimen is typically administered in cycles, with each cycle lasting about 28 days. The specific schedule and dosage may vary depending on the patient's condition and the treating physician's protocol. Generally, cyclophosphamide is given orally or intravenously, while methotrexate and fluorouracil are administered intravenously.

Indications

CMF is primarily indicated for the treatment of early-stage breast cancer, particularly in postmenopausal women. It may be used as an adjuvant therapy following surgery to reduce the risk of cancer recurrence. CMF can also be considered for patients who cannot tolerate more aggressive chemotherapy regimens.

Side Effects

Like all chemotherapy treatments, CMF is associated with a range of side effects. Common side effects include:

• Nausea and vomiting
• Hair loss
• Fatigue
• Mouth sores
• Low blood cell counts, leading to increased risk of infection

Patients receiving CMF are closely monitored for these side effects, and supportive care measures are implemented to manage them.

Efficacy

CMF has been shown to be effective in reducing the risk of breast cancer recurrence and improving survival rates in certain patient populations. However, newer chemotherapy regimens and targeted therapies have been developed, offering additional options for treatment.

Related pages

• Breast cancer
• Chemotherapy
• Adjuvant therapy
• Cancer treatment